SCHEMBL17242554

SCHEMBL17242554

O=c1[nH]c2c(F)c(F)ccc2c(=O)n1Cc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRAP1 Q12931 2/20 0.46
LMNA P02545 4/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 1/20 0.43
TLR7 Q9NYK1 6/20 0.43
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
POLB P06746 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TLR8 Q9NR97 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90B1 P14625 1/20 0.42
CACNA1G O43497 2/20 0.41
HTR3A P46098 2/20 0.41
BRD4 O60885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17241844 0.90 TRAP1 (0.46) TRAP1LMNAHTTALDH1A1HPGD
SCHEMBL17242702 0.89 KDM4E (0.46) TRAP1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL17241498 0.86 KDM4E (0.57) LMNAHTTALDH1A1SMN1; SMN2KDM4E
SCHEMBL17242573 0.82 TRAP1 (0.48) TRAP1LMNAHTTALDH1A1HPGD
SCHEMBL17242500 0.80 KDM4E (0.45) TRAP1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL17242789 0.77 KDM4E (0.56) LMNAHTTALDH1A1SMN1; SMN2KDM4E
SCHEMBL17241716 0.75 CA9 (0.59) LMNAHTTALDH1A1HPGDSMN1; SMN2
SCHEMBL17242758 0.75 DDR1 (0.46) TRAP1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL17242492 0.75 KDM4E (0.41) TRAP1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL17242631 0.75 KDM4E (0.45) TRAP1ALDH1A1HPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170137387-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES ORION CORPORATION (FI) 2017-05-18 US disclosed
EP-3140301-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES Orion Corporation (FI) 2017-03-15 EP disclosed
WO-2015169999-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES ORION CORPORATION (FI) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137387-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES GABRB1, GABRB3, GABRB2 TRAP1 2858/4885LMNA 4675/4885HTT 3829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.